abstract |
The present invention relates to human antibodies that recognize human C5a receptors. By binding to C5aR, the antibody inhibits C5a signal transduction in which pre-inflammatory signals are inhibited. Based on the role of C5a and its receptors in the stimulation of inflammation, the present invention further relates to the therapeutic use of said human anti-C5aR antibodies and in particular to the treatment of immunological disorders. |